AIP
CRSP icon

Ameritas Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

Ameritas Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$462K Buy
8,462
+987
+13% +$52K 0.01% 938
2026
Q1 		$356K Buy
7,475
+278
+4% +$14.7K 0.01% 957
2025
Q4 		$377K Buy
7,197
+282
+4% +$16.9K 0.01% 913
2025
Q3 		$448K Sell
6,915
-1,536
-18% -$88.2K 0.01% 859
2025
Q2 		$411K Buy
+8,451
New +$327K 0.01% 925

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ameritas Investment Partners's CRSP Position: Q2 2026 in Review

Ameritas Investment Partners increased its CRISPR Therapeutics (CRSP) stake by 13% in Q2 2026, buying an estimated $52K and bringing the position to 8,462 shares worth $462K. The position accounts for 0.01% of the portfolio, ranked #938.

Ameritas Investment Partners first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Ameritas Investment Partners held 8,462 shares of CRISPR Therapeutics worth $462K as of Q2 2026.
  • Ameritas Investment Partners bought 987 CRISPR Therapeutics shares in Q2 2026, an estimated $52K.
  • CRISPR Therapeutics made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #938 holding.
  • Ameritas Investment Partners first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.